NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.
Raptor Announces CEO Succession Plan; Dr. Christopher Starr To Retire As CEO At Year-end 2014, Julie Anne Smith Named President And CEO-Designate
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts